Divi’s Laboratories

Select Language Afrikaans Albanian Arabic Armenian Azerbaijani Basque Belarusian Bulgarian Bengali Catalan Chinese (Simplified) Chinese (Traditional) Croatian Czech Danish Dutch English Estonian Filipino Finnish French Galician Georgian German Greek Gujarati Haitian Creole Hebrew Hindi Hungarian Icelandic Indonesian Irish Italian Japanese Javanese Kannada Khmer Korean Latvian Lithuanian Macedonian Malay Maltese Marathi Nepali Norwegian Persian Polish Portuguese Punjabi Romanian Russian Serbian Slovak Slovenian Spanish Swahili Swedish Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Welsh Yiddish

This is a collection of articles archived for the excellence of their content. Additional information may please be sent as messages to the Facebook community, Indpaedia.com. All information used will be gratefully acknowledged in your name.

1990, 2020

Swati Bharadwaj, Divi’s Labs enters Rs 1 lakh crore mcap club, December 18, 2020: The Times of India

Divi’s Laboratories: 1990, 2020
From: Swati Bharadwaj, Divi’s Labs enters Rs 1 lakh crore mcap club, December 18, 2020: The Times of India

City-based Divi’s Laboratories became the second pharma player in the country, after Sun Pharma, to enter the big league of companies with a market capitalisation of Rs 1 lakh crore or more. Led by Reliance Industries, there are just 31 companies, out of a total of about 5,000 companies in India, which can boast of this milestone.

Divi’s has set a blistering pace on the bourses in the past decade: From about Rs 8,000 crore in December 2010, the company’s market value at Thursday’s close was Rs 1.02 lakh crore — a jump of over 12 times during this period. The stock closed the day’s session on BSE at Rs 3,826, more than double from its March low of Rs 1,633. The day the company, a major player in the contract research & manufacturing services space (CRAMS), reached a milestone on the bourses, it had to encounter protest by hundreds of farmers and fishermen at one of its underconstruction plant at Kothapakala village in East Godavari district of Andhra Pradesh. The protesters fear that effluents from the plant may adversely affect their catch.

According to analysts, the main ingredient of the company’s success is its positioning as the one of the key global suppliers of APIs like Naproxen (nonsteroidal anti-inflammatory drug), Detromethorphan (cough suppressant) and Gabapentin (anti-convulsant), a position it attained by edging out some global pharma giants, and sharp focus on CRAMS.